Explore

Companies
Economy
Pulse
Mentions
Industries
Firms & Analysts
Returns

Product

Pricing
Earnings-call intelligence
Blog
About

Company

Contact
Privacy Policy
Terms of Service

Follow

LinkedIn
X
YouTube
TikTok
Instagram
Crunchbase
Product Hunt

Descriptive analysis built from SEC filings and public earnings transcripts. Not investment advice.

Gregory Renza (Truist Securities) — Tellvest

Analysts/Gregory Renza

Gregory Renza

Truist Securities

Healthcare

Limited coverage. Only 3 questions of coverage. Treat these numbers as directional — sample too small for reliable averages.

Companies

Questions

Challenge RatePercentage of questions scored as challenging — where the analyst pushed back, pressed for specifics, or questioned management's assumptions.

Challenge Trend

Q4 '24Q2 '26

Focus Areas5 topics

Innovation & R&D2Competitive Dynamics2Product Launch1Geographic Expansion1Revenue Growth1

Trends3 quarters

Questions per Quarter

Questions

Challenging

Companies Covered

Question History3 questions

AMGNAmgen Inc.2 quarters

2025 Q1

Just curious if you could just elaborate how confident you are on the potential for 410 be best or even better in class as you learn more about this molecule.

Innovation & R&DCompetitive DynamicsView in transcript →

2024 Q4

I'm just wondering if you could comment a bit about the opportunity in China and namely, just about the commercial opportunity for those oncology medicines

Geographic ExpansionRevenue GrowthView in transcript →

REGNRegeneron Pharmaceuticals1 quarter

2026 Q2

what is the realistic time line for the GLP [indiscernible] plus Praluent combination?

Innovation & R&DCompetitive DynamicsProduct LaunchView in transcript →